Travere Therapeutics gains FDA approval for sparsentan in FSGS
Pharmaceutical Technology
Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome.
pharminent
April 14, 2026 (Last updated: April 14, 2026)
Pharmaceutical Technology
Travere Therapeutics has received FDA approval for Filspari to reduce proteinuria in patients aged eight years and over with FSGS without nephrotic syndrome.
